Intellectual Property
The Company has worldwide exclusive license to its products from Mount Sinai School of Medicine and Temple University with right to sublicense. Currently more than 6 patent applications are included in this license. These patent applications cover composition of matter, method of treatment and process of manufacturing these drugs. These applications cover all ofour anticancer compounds. The Company employs its own outside patent counsel who oversees the work of the University patent counsels. Four patents have been issued.
Products in Development
Note: All drugs are covered by distinct patent applications filed and exclusively licensed to AACT. Market projections are for 2020 based on incidence and analyst estimates.
The anticancer drug “AA150030TM” is currently the lead program for development. An IND is planned early 2022.
108600 has been found to be very effective for the treatment of TNBCs and Hormone-refractory prostate cancers and will be the second molecule that is expected to reach the IND phase in 2022.
The second generation RAS mimetics are currently undergoing pre-clinical studies for the treatment of RAS-mutant lung, Colorectal and Pancreatic cancers as well as Acute myeloid leukemias and will enter the IND phase in 2023.
The Company’s manufacturing and pre-clinical development activities are currently outsourced to contract research organizations.